Figure 6.

(A) Associations of MUC16 with the stage; (B) grade of the disease; and (C) decreased overall survival in patients with MIBC subjected to cisplatin‐based chemotherapy. Accordingly, MUC16 was associated with more aggressive bladder tumours, namely advanced stages and grade of the disease. Moreover, its presence in MIBC associates with decreased survival in MIBC subjected to chemotherapy. For (A) and (B), comparisons between data sets were made by chi‐square test (*P < 0.05); in (C), a log‐rank test was performed, P = 0.032. + censored MUC16‐negative tumours; ♦ censored MUC16‐positive tumours.